Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Potential value becomes more plausible if the FY2026-FY2027 setup lasts beyond the assumed fade after FY2027.
FY2027 revenue falls below $53.39 billion.
Reduce. The report-date price of $105.52 stands above Fair value of $86.74, implying -17.8% to the central conclusion.3
Potential value is $139.69, but that outcome depends on stronger and longer growth than the central case assumes.
The main risk is FY2027 revenue below $53.39 billion, the lower end of the analyst forecast range as of September 9, 2026. That would force a lower growth path and reduce profit and cash expectations.1
The clearest upside path assumes Medical Devices grows faster than Abbott beyond FY2027; its FY2025 revenue establishes scale, not that future trend. Diagnostics, Nutrition, and Established Pharmaceuticals must remain profitable, and free cash flow must stay positive. FY2025 operating-income and cash-flow levels establish only the starting point.46
The demand-led upside case requires Abbott to deliver the FY2027 revenue and adjusted-EPS forecasts while Medical Devices remains the main growth contributor.1
Reduce because the report-date price exceeds Fair value despite a constructive near-term operating setup.3
The demand-led upside case requires Abbott to meet the FY2027 revenue and adjusted-EPS forecasts. It also assumes Medical Devices grows faster than Abbott; its FY2025 revenue establishes scale, not that growth trend.16
Reduce because the report-date price exceeds Fair value.3
The manufacture of many of Abbott's products is a highly exacting and complex process, and if Abbott or one of its suppliers or manufacturers encounters problems manufacturing products, Abbott’s business could suffer. The manufacture of many of Abbott’s products is a highly exacting and complex process, due in part to strict regulatory requirements.
In addition, third-party manufacturers and single suppliers are currently used for certain products and materials.
The most damaging operating path combines a revenue-range miss, two weak Medical Devices years, and poorer cash generation. Those events would reduce earnings while investors paid less for each future dollar.
No structural moat is established. FY2025 cash generation supports operating strength, but it does not demonstrate switching costs, software lock-in, distribution control, or another durable barrier.
Cash flow and margins are business outcomes rather than moat sources. They support value only while revenue, profit, and reinvestment economics remain intact.45
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($86.74). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $7.5B after modeled capex of $2.2B, with terminal value at 63.5% of . A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
A beat strengthens the near-term case, but it does not prove growth beyond FY2027.
Healthcare-products industry capital spending equaled 4.5% of revenue and 0.8 times depreciation as of 2026-09-01, retrieved 2026-09-01 04:00:14.
The demand-led upside case requires Abbott to meet the FY2027 revenue and adjusted-EPS forecasts. It also assumes Medical Devices grows faster than Abbott; its FY2025 revenue establishes scale, not that growth trend.
A revenue result below the published FY2027 range would show weaker revenue delivery, not by itself a weaker demand cycle. The shortfall would reduce consolidated profit and cash expectations.
The device peer is the closest operating comparison; three drug peers add mature-healthcare context but have different economics. The mixed set is only a valuation cross-check.
Below a normal portfolio position under the Reduce rating because the report-date price exceeds Fair value. The report-date price exceeds Fair value, while the valuation range is wide.3
Keep the position reduced while the Reduce rating applies and the report-date price exceeds Fair value; consider further reductions if revenue, segment growth, or cash triggers are breached.
Do not initiate exposure while the report-date price remains above Fair value.3
Avoid maintaining a full position; reduce exposure while monitoring FY2027 revenue and Medical Devices growth.1
Cash generation is supportive, but the valuation does not justify adding solely for distributions.4
Reduce exposure because the report-date price of $105.52 exceeds Fair value of $86.74.3
Near-term revenue and adjusted-EPS forecasts are constructive, but they do not establish durable growth after FY2027.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
This path lowers sales, profit, and cash while shortening the period for which investors will pay a premium.
Revenue below $53.39 billion would force a multi-year growth reset, reducing sales, profit, and cash generation. Recovery requires revenue to return inside the published range without weakening cash flow.
Annual segment growth below 2.5% for two years would turn Abbott's largest growth contributor into a drag on consolidated revenue, operating profit, earnings, and cash flow.6
At or below $0.80 of operating cash for each $1.00 of profit, the dividend and cash-based valuation support would weaken. Recovery requires stronger conversion and positive free cash flow.
A rate above 9.2853% would reduce the present value of long-dated cash flows even if operating forecasts were met. Recovery requires lower rates or cash flows above the forecast path.
The five developments that would weaken our investment case.
A breach would show that the expected acceleration is weaker than forecast. Lower sales would reduce operating profit, adjusted earnings, and cash generation across the valuation case.
Current:$54.65 billion mean forecast for FY2027, as of and retrieved 2026-09-09.
Alert ifBelow $53.39 billion for FY2027.
Sustained weakness would reduce Medical Devices sales and profit, pressuring consolidated results. Diagnostics, Nutrition, and Established Pharmaceuticals reported positive FY2025 operating income, but those levels do not establish that they would offset the shortfall.
Current:$21.39 billion of FY2025 segment revenue.
Alert ifAnnual revenue growth below 2.5% for two consecutive fiscal years.
A breach would show that reported profit is no longer producing enough operating cash. Less operating cash would leave less funding for capital spending and distributions, weakening cash-based value support.
Current:$1.47 of operating cash for each $1.00 of reported profit in FY2025.
Alert ifAt or below $0.80 per $1.00 of profit in the latest trailing fiscal year.
A breach would show operating cash no longer covers capital spending. That would remove the internal cash surplus available for dividends, repurchases, debt reduction, and growth investment.
Current:$7.40 billion in FY2025.
Alert ifNegative free cash flow in the latest fiscal year.
A higher required return would reduce what investors pay for distant cash flows. Operating delivery could remain intact while the present value of those future cash flows declined.
Current:7.2853% on 2026-09-09, retrieved 2026-09-09T15:19:12+00:00.
Alert ifAbove 9.2853% within 12 months.
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Limitation: Terminal value is 78.4% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
Solve for the growth rate that makes the model value equal the report-date share price.
The base scenario assumes the FY2027 revenue and adjusted-EPS forecasts are achieved. It then assumes growth fades toward a mature-company pace; that post-FY2027 fade is a valuation premise, not a reported result.1
Broader growth persistence would lift revenue, earnings, and cash beyond the period directly supported by dated forecasts.
Results inside the ranges would be consistent with the FY2027 analyst revenue and adjusted-EPS ranges, but would not establish reported-EPS comparability or growth beyond FY2027.
A miss would weaken the sales, profit, and cash path.
The FY2027 analyst EPS estimate is adjusted, so it should not be treated as directly comparable with reported EPS without reconciling the accounting basis.1
Sales scale drives operating profit and cash generation.
The largest segment has the greatest effect on consolidated results.
Weak conversion leaves less cash for investment and distributions.
Positive cash after capital spending supports distributions and debt reduction.
| $43.08B |
| $43.65B |
| $40.11B |
| $41.95B |
| $44.33B |
| +0.7% |
| Gross profit | $23.21B | $22.32B | $20.04B | $21.33B | $24.61B | +1.5% |
| Operating income | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B | -1.1% |
| Net income | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B | -2.0% |
| EPS (diluted) | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | -1.4% |
| EBITDA | $12.16B | $11.89B | $10.61B | $10.83B | $11.55B | -1.3% |
| R&D | $2.74B | $2.89B | $2.74B | $2.84B | $2.94B | +1.8% |
| SG&A | $11.32B | $11.25B | $10.95B | $11.70B | $12.33B | +2.2% |
Cash generation supports distributions and valuation, but one fiscal year does not prove persistence. Negative free cash flow would remove that support.4
Diluted shares moved from 1.749 billion in FY2023 to 1.748 billion in FY2025, while FY2025 share-based compensation was $664 million. Dilution should remain separately monitored.
The available cash-flow facts establish substantial cash generation, but they do not establish a dated return-on-invested-capital trend.
The established enterprise discount rate was 7.2853% on 2026-09-09; this section makes no return-on-capital spread claim.
Those filed figures anchor the forecast operating-margin path.
Future profit growth depends on revenue delivery and maintaining operating economics near that base.
Capital spending was $2.17 billion in the same fiscal year.
The business presently funds recurring investment from operations, but future reinvestment needs remain material.
| Revenue | $44,328,000,000 |
|---|---|
| Cost of revenue | $19,721,000,000 |
| Gross profit | $24,607,000,000 |
| Operating expenses | $16,554,000,000 |
| Operating income | $8,053,000,000 |
| Non-operating items and tax | -$1,529,000,000 |
| Net income | $6,524,000,000 |
| Total assets | $86,713,000,000 |
|---|---|
| Cash | $8,522,000,000 |
| Current assets | $25,996,000,000 |
| Total liabilities | $33,942,000,000 |
| Current liabilities | $16,496,000,000 |
| Shareholders’ equity | $52,771,000,000 |
| Net income | $6,524,000,000 |
|---|---|
| Operating inflow | $10,304,000,000 |
| Depreciation and amortization | $3,116,000,000 |
| Stock-based compensation | $664,000,000 |
| Operating cash flow | $9,566,000,000 |
| Operating outflow | $738,000,000 |
| Cash available | $17,253,000,000 |
| Beginning cash | $7,616,000,000 |
| Exchange-rate effect | $71,000,000 |
| Investing outflow | $2,422,000,000 |
| Capex | $2,171,000,000 |
| Other investing activities | $251,000,000 |
| Financing outflow | $6,309,000,000 |
| Ending cash | $8,522,000,000 |
| Investing cash flow | -$2,422,000,000 |
| Financing cash flow | -$6,309,000,000 |
Source: SEC EDGAR · Filed 2026-02-20 · SEC EDGAR
| Revenue by operating segment | Revenue | Share | YoY |
|---|---|---|---|
| Medical Devices | $21.4B | 48.2% | 12.6% |
| Diagnostic Products | $8.9B | 20.2% | -4.3% |
| Nutritional Products | $8.5B | 19.1% | 0.5% |
| Established Pharmaceutical Products | $5.5B | 12.5% | 6.6% |
Source: SEC EDGAR · Filed 2026-02-20 · SEC EDGAR
| Revenue by geography | Revenue | Share | YoY |
|---|---|---|---|
| United States | $17.1B | 38.6% | 4.9% |
| All Other | $16B | 36% | 8.1% |
| Germany | $2.8B | 6.2% | 8.7% |
| China | $1.9B | 4.3% | -9.7% |
| Switzerland | $1.9B | 4.2% | 7.1% |
| India | $1.9B | 4.2% | 3% |
| Japan | $1.5B | 3.3% | 2.4% |
| United Kingdom | $1.3B | 3% | 13.1% |
Point-in-time financial data used in the 2026-09-09 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $20.9B | $3.1B | $1.4B | $3.2B | $2.1B | $1.1B | $1.4B | $310M | $522M | $1.5B | — | -$248M | $11.1B | — | $18.6B | $18.8B | $20.7B | 14.5% | — | 5.7% | — |
| 2017-12-31 | $27.4B | $6.1B | $477M | $5.6B | $4.4B | $1.1B | $3B | $406M | $117M | $1.8B | — | -$9.6B | -$5.3B | $18.6B | $9.4B | $9.6B | $27.7B | 5.7% | — | 6.1% | — |
| 2018-12-31 | $30.6B | $6.9B | $2.4B | $6.3B | $4.9B | $1.4B | $3.3B | $477M | $238M | $2B | — | -$1.4B | -$10.4B | $9.4B | $3.8B | $4.1B | $19.4B | 11.9% | — | 6.7% | — |
| 2019-12-31 | $31.9B | $7.9B | $3.7B | $6.1B | $4.5B | $1.6B | $3B | $519M | $718M | $2.3B | — | -$1.8B | -$4.3B | $3.8B | $3.9B | $4.1B | $17.9B | 14.2% | — | 6.0% | — |
| 2020-12-31 | $34.6B | $9B | $4.5B | $7.9B | $5.7B | $2.2B | $3.3B | $546M | $403M | $2.6B | — | -$2.2B | -$2.8B | $3.9B | $6.8B | $7.1B | $18.5B | 15.5% | — | 3.8% | — |
| 2021-12-31 | $43.1B | $12.2B | $7.1B | $10.5B | $8.6B | $1.9B | $3.5B | $640M | $2.3B | $3.2B | — | -$2B | -$5.5B | $6.8B | $9.8B | $10.2B | $18.1B | 19.6% | — | 4.3% | — |
| 2022-12-31 | $43.7B | $11.9B | $6.9B | $9.6B | $7.8B | $1.8B | $3.3B | $685M | $3.8B | $3.3B | -$699M | -$1.7B | -$7.6B | $9.8B | $9.9B | $10.2B | $16.8B | 19.2% | — | 6.7% | — |
| 2023-12-31 | $40.1B | $10.6B | $5.7B | $7.3B | $5.1B | $2.2B | $3.2B | $644M | $1.2B | $3.6B | -$2.5B | -$3.1B | -$7.1B | $9.9B | $6.9B | $7.3B | $14.7B | 16.2% | — | 6.7% | — |
| 2024-12-31 | $42B | $10.8B | $13.4B | $8.6B | $6.4B | $2.2B | $3.2B | $673M | $1.3B | $3.8B | -$537M | -$2.3B | -$5.4B | $6.9B | $7.6B | $8B | $14.1B | 16.3% | — | 7.3% | — |
| 2025-12-31 | $44.3B | $11.6B | $6.5B | $9.6B | $7.4B | $2.2B | $3.1B | $664M | $893M | $4.1B | -$1.6B | -$2.4B | -$6.3B | $7.6B | $8.5B | $8.9B | $12.9B | 18.2% | — | 7.3% | — |
Abbott Laboratories (ABT) trades at 17.9x forward earnings against a peer median of 14.6x. Its EV/EBITDA of 18.0x compares with a peer median of 13.6x. The comparison uses 4 peers: Medtronic plc, Gilead Sciences Inc., Pfizer Inc. and AbbVie Inc., as of 2026-09-08 to 2026-09-09.
| Above Fair value | Reduce exposure rather than add because the Reduce rating applies while the report-date price exceeds Fair value. | The accepted midpoint is below the report-date price. |
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Limitation: Terminal value is 63.5% of this model's value, above the 60% level at which the methodology flags concentration; the value leans on the years beyond the explicit forecast.
Value each distinct segment, subtract corporate overhead and net debt, add probability-weighted optionality, and divide by diluted shares.
| $9.28B |
| $10.15B |
| $10.35B |
| $10.56B |
| $10.77B |
| $11.01B |
| $11.25B |
| $11.53B |
| $11.82B |
| $12.12B |
| NOPAT | $7.51B | $8.22B | $8.38B | $8.55B | $8.72B | $8.92B | $9.11B | $9.34B | $9.57B | $9.81B |
| Residual cash after reinvestment policy | $7.51B | $8.22B | $8.38B | $8.55B | $8.72B | $8.92B | $9.11B | $9.34B | $9.57B | $9.81B |
| Revenue growth | 13.5% | 8.6% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
| Operating margin | 18.4% | 18.6% | 18.5% | 18.4% | 18.3% | 18.3% | 18.2% | 18.2% | 18.2% | 18.2% |
| Tax rate | 19.1% | 19.1% | 19.1% | 19.1% | 19.1% | 19.1% | 19.1% | 19.1% | 19.1% | 19.1% |
| Reinvestment rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
| Gilead Sciences Inc. |
| 14.8x |
| 6.0x |
| 13.9x |
| -20.7% |
| 33.7% |
| PFE | Pfizer Inc. | 9.6x | 2.5x | 8.3x | 5.0% | 27.9% |
| ABBV | AbbVie Inc. | 15.3x | 6.8x | 16.8x | 62.2% | 40.0% |
